Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer

PURPOSE: Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed. EXPERIMENTAL DESIGN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Belli, Valentina, Sforza, Vincenzo, Cardone, Claudia, Martinelli, Erika, Barra, Giusi, Matrone, Nunzia, Napolitano, Stefania, Morgillo, Floriana, Tuccillo, Concetta, Federico, Alessandro, Dallio, Marcello, Loguercio, Carmelina, Gravina, Antonietta Gerarda, Palma, Raffaele De, Ciardiello, Fortunato, Troiani, Teresa
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620258/
https://ncbi.nlm.nih.gov/pubmed/28978118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados